Company intelligence / Profile preview
Broaden Biopharma
Suzhou, Jiangsu, Chinabroadenbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Broaden Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform to address infectious diseases and oncology. Its lead programs include mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV), as well as innovative mRNA-encoded protein therapies for cancer. Broaden Biopharma aims to provide high-quality, accessible mRNA solutions through its integrated R&D and manufacturing capabilities.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- mRNA-based drugsLipid nanoparticle delivery therapyVaccine
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Broaden Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Broaden Biopharma.